36 results on '"Balmanno, Kathryn"'
Search Results
2. Supplementary Data from Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
3. Supplementary Data from Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
4. IKKα plays a major role in canonical NF-κB signalling in colorectal cells
5. Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
6. An mTORC1-to-CDK1 Switch Maintains Autophagy Suppression during Mitosis
7. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance
8. Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
9. Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK
10. ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death
11. RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence
12. Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
13. Estimation of the In Vitro and In Vivo Inhibitory Effects of Antifolates upon Thymidylate Synthase (TS) in Whole Cells
14. Adaptation to chronic mTOR inhibition in cancer and in aging
15. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
16. Regulation of MEK/ERK pathway output by subcellular localization of B-Raf
17. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
18. CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL
19. Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
20. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
21. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics
22. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL
23. The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1
24. The conditional kinase ΔMEKK1:ER* selectively activates the JNK pathway and protects against serum withdrawal-induced cell death
25. Extracellular Signal-regulated Kinases 1/2 Are Serum-stimulated “BimEL Kinases” That Bind to the BH3-only Protein BimEL Causing Its Phosphorylation and Turnover
26. ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
27. ΔRaf-1:ER* Bypasses the Cyclic AMP Block of Extracellular Signal-Regulated Kinase 1 and 2 Activation but Not CDK2 Activation or Cell Cycle Reentry
28. Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1
29. Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim
30. Activation of ERK1/2 by ΔRaf-1 : ER* represses Bim expression independently of the JNK or PI3K pathways
31. ΔMEKK3:ER* activation induces a p38α/β2-dependent cell cycle arrest at the G2 checkpoint
32. Regulation of Cell Cycle Re-entry by Growth, Survival & Stress Signalling Pathways
33. Both MAP Kinase and PI3′-Kinase are required for cell cycle re-entry in quesicent CCI39 cells but MAPK is not required for asynchronous growth
34. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells
35. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer
36. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.